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1. Introduction 
Primary Sclerosing Cholangitis (PSC) is a chronic hepatobiliary disease characterized by 
progressive inflammation and fibrosis of the intra and extra biliary tree. This phenomenon 
leads to diffuse stricturing of the biliary tree and, if left untreated, can result in cirrhosis, 
portal hypertension and end stage liver disease. There are treatments aimed at delaying the 
progression of disease and reducing symptoms. However, the definitive treatment at the 
end stage of this disease is liver transplant.  
The etiology and pathogenesis of the disease is largely unknown although some researchers 
have speculated that immunologic and genetic factors may be involved. Ulcerative colitis 
(UC) is also a chronic inflammatory disorder of the colon of unknown etiology with possible 
genetic and environmental triggers. The correlation between both these diseases would 
suggest that the etiology could be immune mediated.  
2. Immune system involvement 
Current theories postulate that an autoimmune process leading to lymphocytic infiltrate 
causes biliary destruction (Aron 2009). Some studies have found an increased number of 
serum autoantibodies being expressed in patients with PSC. For example, antineutrophil 
cytoplasmic, antinuclear, and anticardiolipin antibodies are seen with increased frequency 
in PSC (Angulo 2000). A study of 73 patients with definite PSC found that 81% were positive 
for the above listed antibodies (Angulo 2000). Also, a study of 25 PSC patients showed that 
75% tested positive for pANCA (Gur 1995). These serum markers lack specificity for PSC. 
Nonetheless, the involvement of the immune system remains apparent. 
In addition, some other autoimmune disorders are associated with the occurrence of PSC. A 
few case reports found males under the age of 25 that were diagnosed with PSC, to have UC 
and Type 1 Diabetes Mellitus (Gluch 1999 and Kay 1993). Chronic liver diseases, such as 
Primary Biliary Cirrhosis and Autoimmune Hepatitis have also been noted to have some 
overlapping features. More importantly, there is evidence that PSC has significant overlap 
features with autoimmune hepatitis. Three patients with elevated liver function tests, 
positive Antinuclear Antibody and/or Anti-smooth muscle antibodies were found to have 
histological and cholangiographic evidence of PSC (Gohike 1996). This supports the overall 
theory that the immune system is significantly involved with the development of PSC.  
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Undoubtedly an association between UC and PSC exists, however the mechanism by which 
they are related remains largely unknown. Some have suggested that a shared autoantibody 
between biliary and colon epithelium exists. An epitope that was common to the colon and 
biliary epithelial cells was discovered. Using this finding, a study was conducted to 
determine if a cross-reactive antibody exists that is common to PSC and UC (Mandal 1994). 
This study found that sera from patients with PSC contained autoantibodies against a cross-
reactive peptide shared by colon and biliary epithelial cells. Therefore, this antibody could 
suggest a molecular association between PSC and UC. 
Based on the premise that PSC and UC are strongly related, some theorist have postulated 
that infectious agents may be involved in the development of PSC. That is, when the colonic 
mucosa is significantly inflamed, toxic agents can invade the blood circulation and thereby 
cause PSC. 26 patients with AIDS-related cholangiopathy were found to have CMV and 
Cryptosporidium infection (Benhamou 1993). The most common infectious agents isolated 
from patients with AIDS-related cholangiopathy include microsporidium and 
cryptosporidium. Non-infectious agents have been linked to the development of PSC. For 
example, patients receiving hepatic artery infusion of chemotherapeutic agents were 
reported to have cholangiographic evidence of PSC (Barnett 2001). However, UC disease 
activity does not correlate with the appearance of PSC. 
3. Genetics 
The understanding of certain genetic associations between US and PSC has gained increased 
importance. For example, one study illustrated that several members of three families had 
PSC and UC (Quigley 1983). It has been suggested that specific human leukocyte antigen 
(HLA) haplotypes may be more likely to occur in the setting of well-defined PSC. Several 
specific HLA haplotypes have been found to strongly correlate with the development of 
PSC. In one study, HLA-DRw52a was present in 100% of 29 patients studied with PSC 
(Prochazka 1990). Also, of these patients 15 shared a common haplotype 12 of who had 
previously diagnosed UC (Prochazka 1990). The most common haplotypes associated with 
PSC include the following: HLA-B8, DR3, Dr2 and DR6 (Prochazka 1990). Also, in patients 
with both PSC and UC an increased presence of MICA and MICB alleles were demonstrated 
(Wiencke 2001). These alleles are primarily expressed in the gastrointestinal epithelium 
(Wiencke 2001). Some authors have suggested that this may represent a link between colonic 
and biliary disease. However, whether one specific gene is involved with the occurrence of 
PSC remains controversial.  
The use of certain HLA haplotypes to determine disease progression is also under 
investigation. One study found that the HLA-DR3, DQ2 heterozygote genotype was 
associated with rapid progression of PSC and that the DR4, DQ8 haplotype was related to 
the development of cholangiocarcinoma (Boberg 2001). This finding could have an impact 
on determining disease progression. However, this genetic association requires further 
investigation before it can take center stage in determining prognosis and therapy. 
4. Epidemiology 
PSC is most often seen in Northern European populations. In some Nordic countries it is 
considered the primary indication for liver transplant (16). According to the NIH, PSC 
affects less than 200,000 people in the United States Population. This disease is most 
commonly seen between the ages of 20-30 years and is most common in men. PSC occurs in 
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5 % of patients with UC, and, conversely, UC occurs in 60-75 % of patients with PSC. The 
mean survival is 10- 12 years after diagnosis, with an increased risk for cholangiocarcinoma. 
Despite the known association with UC, there is a small subset of patients with 
retroperitoneal fibrosis who have been diagnosed with PSC (Bartholomew 1963). There are 
varying reports of the actual incidence and prevalence of PSC, which is likely due to the 
inconsistency in its presentation and lack of sufficient data. A population-based study in the 
United States demonstrated that the incidence of PSC was approximately 0.54 to 1.3 per 
100,000, and the prevalence is 6.3 to 20.9 per 100,000 (Bambha 2009). Most of the patients 
described in this study had underlying UC.  
5. Clinical presentation and diagnosis 
Most patients are initially asymptomatic and therefore present with abnormal liver function 
tests or hepatomegaly on physical exam. The most common lab abnormalities include, an 
elevated serum alkaline phosphatase level, usually twice the upper limit of normal, and an  
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elevated Gamma glutamyltransferase. Also, the serum bilirubin and transaminases will 
demonstrate a cholestatic pattern. PSC develops insidiously and symptoms are often non-
specific in their initial presentation. However, as the disease progresses, the most notable 
symptoms include, jaundice, right upper quadrant pain, pruritis, fever, weight loss and 
fatigue. Waxing and waning symptoms are typical of PSC.  
The diagnosis of PSC can be confirmed by liver biopsy or characteristic changes on 
cholangiogram. Endoscopic Retrograde Cholangio Pancreatography (ERCP) has been 
considered the gold standard in diagnosing PSC. However, ERCP is more invasive in 
 
 
Fig. 2. Early PSC in a 45-year-old man with ulcerative colitis and elevated results of liver 
function tests. Coronal MRCP image shows a stricture at the distal common bile duct 
(arrowhead), extrahepatic and left intrahepatic ductal dilatation and irregularity, and a 
subtle stricture at the bifurcation of the posterior right hepatic duct (arrow). (Vitellas K M et 
al. Radiographics 2000;20:959-975) 
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Fig. 3. Stage 2 lesion (Lee, Young-Mee, Kaplan M. Primary sclerosing cholangitis. NEJM 1995) 
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comparison to Magnetic Resonance CholangioPancreatography (MRCP), which has 
comparable accuracy. In cases with a high pretest probability of PSC with a negative MRCP, 
an ERCP would be indicated to visualize small ductal disease. The characteristic findings on 
imaging include, multiple segmental strictures with intervening segments that appear 
normal, otherwise known as a “beaded appearance”(figure 1). Figure 2 is an image of a 
patient with UC and abnormal LFTS that was found to have a stricture in the common bile 
duct and the bifurcation of the hepatic duct, with luminal irregularities. 
Liver biopsy is not indicated for diagnosis in cases with a positive finding on 
cholangiogram. However, liver histology can be useful in staging the disease. The 
characteristic histological feature of PSC is the “onion skin appearance”, which occurs due 
to periductal fibrosis (figure 3). However, this finding is rarely found on biopsy specimens. 
Stage 1 is defined as the portal triad of edema, scarring and mono/polynuclear cell infiltrate 
(figure 4). Stage 1 remains confined to the portal triad. Stage 2 refers to expansion of the 
portal triads with fibrosis into parenchyma (fig 3). Stage 3 and 4 are defined by bridging 
fibrosis and eventual cirrhosis.  
6. PSC & UC association 
There is a high prevalence of UC in patients with PSC while a minority of patients with UC 
have PSC as an extra intestinal manifestation. The current data approximates that 50-75% of 
all patients with PSC have IBD, and in contrast the incidence of patients with UC 
developing PSC is 2.5-7.5 % (Raj 1999). This association is an important one for many 
reasons. A study of 1500 cases of UC established that 3.7 % had PSC and within this subset 
the prevalence of substantial colitis was 5.5%, in contrast to 0.5 % with distal colitis 
(Olsson1991). This suggests that cases with more severe and extensive UC are more likely to 
develop PSC. However, a few case reports have demonstrated a milder course of colonic 
disease in patients that developed PSC (Schrumpf 2001 ad Moayyeri 2005). Therefore, 
regardless of the strong association between these two diseases, for the most part they seem 
to progress autonomously.  
The definitive treatment for UC when patients remain refractory to medical management is 
surgery. Proctocolectomy with ileal reservoir is the most widely accepted surgical 
procedure. A common issue with this ileal reservoir, referred to as the pouch, includes the 
development of pouchitis. This diagnosis is characterized by diarrhea that is occasionally 
bloody and abdominal discomfort. In the subset of UC patients that develop PSC, pouchitis 
after ileal pouch-anal anastomosis (IPAA) is being diagnosed with increasing frequency.  
A study was performed to determine the frequency of pouchitis in patients with and 
without PSC who had an IPAA for UC (Penna 1995). Patients with indeterminate colitis or 
other constructions of reservoirs were excluded in this study. The results showed that one or 
more episodes of pouchitis occurred in 63% of patients with PSC (Penna 1995). In addition, 
of these patients the overall risk for pouchitis increased at 1, 2, 5, and 10 years after IPAA.  
Interestingly Aitola et al also demonstrated that patients with PSC had more chronic, but 
not acute inflammation in the pouch mucosa than patients without cholangitis (Aitola 1998). 
In comparison to patients receiving IPAA for other diseases such as Familial Adenomatous 
Polyposis, the frequency of pouchitis was higher in the PSC-UC patient. Therefore, based on 
this data it is unlikely that the cause of pouchitis is surgery and more likely a consequence of 
PSC-UC. A matched case control study was performed to describe the clinical features and 
outcomes in patients with PSC and IBD. This study found that a significant number of 
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patients in the PSC-IBD group developed back wash ileitis and had an increased incidence 
of colorectal neoplasia (Loftus 2005). 
Some speculate that the significant bowel inflammation is due to a possible change in bile 
acid fecal output. This phenomenon is thought to lead to the development of pouchitis, but, 
this is purely speculation. Nonetheless, an underlying immunologic association exists 
between UC-PSC patients and the later development of pouchitis.  
7. Malignancy 
In comparison to the general population, patients with PSC are at higher risk for developing 
Cholangicarcinoma. This malignancy is defined as an adenocarcinoma of the biliary ducts 
that is rapidly progressive, with an average life expectancy of 5 months at the time of 
diagnosis. It is considered a rare disease within the general population, with a lifetime risk 
of less than 1 %. In contrast, PSC patients have an estimated lifetime risk of 10-15% for 
developing cholangiocarcinoma (Berqquist 2002). This disease is the second leading cause of 
death in PSC patient. Cholangiocarcinomas are most commonly found in the common 
hepatic duct or common bile duct, but can also be detected at the cystic duct. The sites at 
which this disease originates allows rapid dissemination to the liver, gallbladder, pancreas 
and duodenum. Also, intra-peritoneal seeding is not an uncommon consequence of this 
disease. Therefore, cholangiocarcinoma is most frequently diagnosed when it’s metastatic. 
The pathogenesis of PSC is believed to be due to chronic inflammation and obstruction of 
the bile ducts. This ongoing insult to the biliary epithelium is believed to result in malignant 
conversion of the biliary epithelium. In support of this theory, south Asian patients with 
Clonorchis sinesis were at increased risk for developing cholangiocarcinoma (Schwartz 
1986). The precise molecular mechanism by which chronic inflammation leads to 
cholangiocarcinoma still remains unclear.  
Early diagnosis of cholangiocarcinoma is important, especially in PSC patients because it is 
considered a contraindication to liver transplantation. The diagnosis of Cholangiocarcinoma 
in PSC patients is significantly difficult. The use of tumor markers to detect early disease has 
been studied. The CA 19-9 and carcinoembryonic antigen (CEA) has been noted to be 
significantly elevated in patients with cholangiocarcinoma. However, whether they are 
useful as markers of early cholangiocarcinoma is debatable. A study was conducted to 
investigate the utility of measuring CA 19-9 and CEA in patients with PSC for early 
diagnosis of cholangiocarcinoma (Bjournsson 1999). This study found that the levels of CA 
19-9 could rise along with elevations in alkaline phosphatase, which indicates a relapse of 
PSC. However, the sensitivity of the combination of CA 19-9 and CEA was low, but the 
specificity was high (88%). Bile levels of these tumor markers were evaluated in this study 
and didn’t reveal any clinically useful differences. Therefore, the use of these tumor markers 
for detection of cholangiocarcinoma remains controversial.  
The use of conventional radiologic imaging such as Magnetic resonance or CT scans are of 
low sensitivity in diagnosing cholangiocarcinoma. Patients with PSC often have 
cholangiographic evidence of biliary strictures, which make malignant strictures 
indistinguishable. Hence, obtaining tissue is essential for diagnosis. The use of advanced 
endoscopic techniques, such as, Endoscopic Ultrasound (EUS) with fine needle aspiration 
(FNA) is increasingly important for obtaining cytology.  
The combination of brush cytology and FNA increases sensitivity for diagnosis of 
Cholangiocarcinoma  (Eloubeidi 2004). The reported sensitivity of EUS with FNA is 89 % 
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(Eloubeidi 2004). Figure 5 is an image of EUS diagnosing cholangiocarcinoma. Other 
endoscopic techniques, such as Intraductal Ultrasound (IDUS) and Choledoscopy have 
increased sensitivity in cases of negative brush cytology or tissue biopsy using EUS. IDUS 
uses a smaller caliber probe that can be passed through an endoscope into the biliary and 
pancreatic duct. This procedure increases the sensitivity of the ultrasound to detect lesions 
in the pancreatic or biliary ducts. In PSC patients, this technique can assist in distinguishing 
between benign and malignant strictures (Tischendorf  2007). Cholangioscopy is also useful 
because it allows for direct visualization of the biliary stricture (Figure 6). The use of these 
endoscopic procedures increases the overall sensitivity for detection of cholangiocarcinoma 
especially in patients with PSC.  
 
 
Fig. 5.  
UC has a well-known association with the development of colorectal neoplasia. The risk in 
these patients increases with the duration and extent of disease. A study published in the 
New England Journal of Medicine found that the relative risk of colorectal cancer (CRC) was 
14.8 for patients with pan colitis, 2.8 for those with left-sided colitis, and 1.7 for those with 
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Proctitis (Ekbom 1990). It has been suggested that patients with both PSC and UC are at 
even higher risk for CRC. A cohort study was performed comparing patients with UC and 
PSC, and random samples of UC controls without PSC (Shetty 1999). These patients were 
analyzed from diagnosis of the disease until an outcome. They found that thirty-three  (25%) 
of 132 UC patients with PSC developed CRC or dysplasia compared with 11 (5.6%) of 196 
controls (adjusted relative risk 3.15, 95% confidence interval 1.37-7.27) (Shetty 1999). They also 
found that patients with PSC and CRC were more likely to have more proximal and advanced 
CRC. This finding has a significant impact on disease surveillance and management. 
 
 
Fig. 6. Bile duct tumor on direct video cholongioscopy (www.cpmc.org/liver) 
There are several theories regarding the pathogenesis of CRC in patients with PSC and UC. 
Some suggest that the increased bile acids in the colon may contribute to the development of 
dysplasia. Based on this notion, a study was conducted to evaluate the effect of 
ursodeoxycholic acid in preventing the occurrence of colonic dysplasia. This was a cross-
sectional study that evaluated patients with UC and PSC that were undergoing routine 
endoscopic colonic surveillance. This study found that ursodiol use was associated with a 
statistically significant decrease in prevalence of colonic dysplasia (Tung 2001). However, 
this medication has not been evaluated in prospective study, therefore its utility remains 
controversial.  
The risk of CRC has been noted to increase with the length of UC exposure. PSC patient are 
a t even higher risk for CRC and therefore require yearly surveillance colonoscopies (Eaden 
2002). It has been suggested that the cumulative risk of CRC in PSC patients is estimated to 
be 9 % after 10 yrs, 31% after 20 yrs and 50 % after 25 yrs of disease (Broome 1995). A study 
of PSC patients undergoing Liver transplants with hx of UC and pancolitis were found to be 
at increased risk of CRC (Silva 2004). Therefore, in post-transplant patients yearly 
colonoscopies are still recommended.  
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8. Medical treatment for PSC 
Various medications have been studied to evaluate whether they would have a curative role 
in PSC. Immunosuppressive medications have been extensively studied because of their role 
in suppressing inflammatory cytokines. These medications include, glucocorticoids, 
azathioprine, methotrexate, and pentoxifylline. It has been postulated that the upregulation 
of inflammatory cells leads to biliary ductal destruction. Bharucha et al gave 20 patients 
with PSC sustained release pentoxifylline for approximately one year. The serum bilirubin, 
transaminases and alkaline phosphatase were followed every three months. The overall 
study showed no significant improvements in the liver biochemistry and the disease 
(Bharucha 2000). Also, a prospective study using pulse dosing of methotrexate was 
conducted on patients with clinical and histologic evidence of PSC (Knox 1994). This study 
also showed no significant benefit in preventing the progression of PSC. Therefore, the data 
overwhelmingly shows that these immunosuppressive agents are unable to halt the 
progression of the disease.  
The use of ursodeoxycholic acid (UDCA) may have a role in reducing the levels of the liver 
biochemistries. UDCA assists in the regulation of cholesterol by reducing the rate at which 
the intestine absorbs cholesterol. Some studies have suggested that it acts as an 
immunosuppressant. In PSC patients, UDCA is thought to be protective to the cholangiocytes 
by reducing bile exposure. Some studies have shown a mild improvement in serum liver 
chemistry, however the evidence on liver histology remains unchanged. A study was done to 
evaluate the use of high dose UDCA to determine whether the change in the bile acid pool 
would affect the outcome of PSC patients (Cullen 2008). Thirty-one patients were randomized 
to 10 mg/kg, 20 mg/kg or 30 mg/kg of UDCA daily for 2 years. They found that the higher 
doses of UDCA were well tolerated and the mayo survival risk score improved over 1-4 year 
period. However, some other studies have found contradicting results. A study also aimed at 
evaluating high dose UDCA and its effects on survival, symptoms, and quality of life was 
conducted. This study was a randomized placebo-controlled trial that included 219 patients 
followed for a 5-year period (Olsson 2005). The endpoints included quality of life 
assessments, changes in liver biochemistry, death and liver transplantation. They found that 
the serum alkaline phosphatase and alanine aminotransferase decreased within the first 6 
months. However, there were no significant differences in overall symptoms, survival and 
quality of life. Despite the findings of an initial decrease in liver biochemistry, the use of 
UDCA as an aid in symptomatic management still remains controversial.  
Managing the complications associated with PSC with use of medications and supplements is 
still useful. These complications include the development of bacterial cholangitis, deficiency in 
fat-soluble vitamins and pruritis. In PSC, recurrent episodes of bacterial cholangitis is not 
uncommon and if not managed appropriately can become life threatening. Antibiotic 
prophylaxis can be used and is helpful in these recurrent cases. Any procedure that involves 
manipulation of the biliary always requires antibiotic prophylaxis. The antibiotics 
commonly used are cephalosporins, fluroquinolones and beta lactamase inhibitors. 
Ultimately, these patients will require liver transplantation given the severity of the disease. 
9. Prognostic models 
In an effort to appropriately counsel patients regarding prognosis, models have been created 
to predict survival and indication for liver transplant. The most popular models include, 
Mayo clinic, Kings College, Multicenter, and Revised Mayo (Table 1).  
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Age Age Age Age 
Bilirubin Bilirubin Bilirubin Hepatomegaly 
Histologic Stage Albumin Splenomegaly Splenomegaly 
Hemoglobin AST Histologic Stage Histologic Stage 
IBD Variceal Bleed  Alkaline Phosphatase 
Table 1. Predictors of Survival 
The Mayo clinic model was able to predict blood usage, length of stay in ICU and 
occurrence of significant complications in patients undergoing liver transplant (Dickson 
1992 and Kim 1999). 
The revised Mayo Model predicts survival based upon age, liver biochemistry and history 
of variceal bleed (Kim 2000). The estimated probability of survival is based on a scale over 1-
4 yr period. The Multicenter Model was based upon a survival analysis that identified 
significant variables, which predicted survival in approximately four hundred patients with 
PSC (Dickson 1992). The Kings College Model was based upon a multivariate analysis that 
found hepatomegaly, splenomegaly, serum alkaline phosphatase and histologic stage to be 
independent prognostic factors (Farrant 1991). All of these models utilize mathematic 
formulas to determine the management of PSC. The models can be used to assess the 
appropriate time to consider liver transplant. Also, it helps to determine survival post liver 
transplant. The Child-Pugh classification can also be used to determine overall survival. 
These models however, are unable to predict the development of associated malignancies or 
harmful effects of PSC.  
Determining the rate of recurrence of PSC post-transplant has also been evaluated. A large 
cohort study was conducted, which followed patients for 55 months after liver transplant 
(Graziadei 1999). This study found that 20 % of PSC patients developed histologic features 
of PSC and biliary strictures. Also, the average time to diagnosis of PSC was 360 and 1350 
days respectively. However, this study was unable to delineate the factors that lead to the 
recurrence of PSC. In the current literature, there is limited information on what clinical 
variables may influence recurrence. A retrospective analysis was performed, which focused 
on the risk factors leading to allograft failure in PSC patients (Alexander 2008). The three 
most important factors that lead to failure included; acute cellular rejection, steroid-resistant 
acute cellular rejection and HLA-DRB1 association. These findings suggest that a strong 
immunologic association exist. What implications this may have on future liver transplant 
decision-making remains controversial.  
10. Conclusion 
Primary Sclerosing Cholangitis is a well known but uncommon extraintestinal manifestation 
of Ulcerative Colitis. This disease association can have a significant impact on the overall 
management and prognosis of both diseases. The focus of this literature review and chapter 
was to present the most current understanding of the pathophysiology, diagnosis and 
management of PSC as an extra intestinal manifestation of UC and to enumerate the special 
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circumstances pertaining to patients having both diseases. Overall, the reader should have 
gained an understanding of the many ways in which PSC can manifest and how the 
association with UC can alter their overall management and prognosis. 
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